Journal
HUMAN REPRODUCTION
Volume 27, Issue 11, Pages 3123-3131Publisher
OXFORD UNIV PRESS
DOI: 10.1093/humrep/des286
Keywords
ethics; prenatal diagnosis; aneuploidy
Categories
Funding
- NIH [P50 HG003389, 1 U54 RR024374-01A1]
- Ariosa Diagnostics
Ask authors/readers for more resources
The recent release of new, non-invasive prenatal tests for fetal aneuploidy using cell-free fetal DNA (cffDNA) has been hailed as a revolution in prenatal testing and has triggered significant commercial interest in the field. Ongoing research portends the arrival of a wide range of cffDNA tests. However, it is not yet clear how these tests will be integrated into well-established prenatal testing strategies in the USA, as the timing of such testing and the degree to which new non-invasive tests will supplement or replace existing screening and diagnostic tools remain uncertain. We argue that there is an urgent need for policy-makers, regulators and professional societies to provide guidance on the most efficient and ethical manner for such tests to be introduced into clinical practice in the USA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available